Ocugen 8-K: Officer/Director Changes, Compensation & Exhibits
Ticker: OCGN · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1372299
| Field | Detail |
|---|---|
| Company | Ocugen, INC. (OCGN) |
| Form Type | 8-K |
| Filed Date | Jan 8, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: executive-changes, compensation, corporate-governance
TL;DR
**Ocugen filed an 8-K about executive changes and compensation, watch for details.**
AI Summary
Ocugen, Inc. filed an 8-K on January 8, 2024, reporting an event that occurred on January 2, 2024. The filing indicates information related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers' and 'Financial Statements and Exhibits'. This matters to investors because changes in executive leadership or their compensation can signal shifts in company strategy, financial health, or future performance, potentially impacting stock valuation.
Why It Matters
Changes in leadership and executive compensation can directly influence a company's direction and financial stability, which are key factors for stock performance.
Risk Assessment
Risk Level: medium — While the filing itself is routine, the underlying events it refers to (executive changes, compensation) can carry significant risk or opportunity depending on the specifics, which are not detailed in this summary.
Analyst Insight
Investors should monitor subsequent filings or company announcements for specific details on the executive changes and compensation, as these will provide the actual context and potential impact on Ocugen's future.
Key Numbers
- $0.01 — par value per share (of Ocugen's Common Stock)
- 001-36751 — Commission File Number (identifies Ocugen's filings with the SEC)
- 1934 — Securities Exchange Act (under which the report is filed)
Key Players & Entities
- Ocugen, Inc. (company) — the registrant filing the 8-K
- The Nasdaq Stock Market LLC (company) — the exchange where Ocugen's common stock is registered
- 001-36751 (dollar_amount) — Commission File Number
- January 2, 2024 (date) — Date of Earliest Event Reported
- January 8, 2024 (date) — Date of Report (filing date)
Forward-Looking Statements
- Ocugen will release more detailed information regarding the executive changes and compensation arrangements. (Ocugen, Inc.) — high confidence, target: Q1 2024
FAQ
What is the earliest event date reported in this 8-K filing by Ocugen, Inc.?
The earliest event reported in this 8-K filing by Ocugen, Inc. occurred on January 2, 2024.
What specific items of information are covered in this 8-K filing according to the 'ITEM INFORMATION' section?
This 8-K filing covers 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers' and 'Financial Statements and Exhibits'.
On which stock exchange is Ocugen, Inc.'s Common Stock registered?
Ocugen, Inc.'s Common Stock, with a $0.01 par value per share, is registered on The Nasdaq Stock Market LLC.
What is the business address and phone number for Ocugen, Inc. as listed in the filing?
Ocugen, Inc.'s business address is 11 Great Valley Parkway, Malvern, Pennsylvania 19355, and their business phone number is (484) 328-4701.
What is the Central Index Key (CIK) for Ocugen, Inc.?
The Central Index Key (CIK) for Ocugen, Inc. is 0001372299.
Filing Stats: 630 words · 3 min read · ~2 pages · Grade level 12.7 · Accepted 2024-01-08 06:05:28
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value per share OCGN The Nasdaq
Filing Documents
- tm242262d1_8k.htm (8-K) — 27KB
- tm242262d1_ex10-1.htm (EX-10.1) — 48KB
- 0001104659-24-001990.txt ( ) — 253KB
- ocgn-20240102.xsd (EX-101.SCH) — 3KB
- ocgn-20240102_lab.xml (EX-101.LAB) — 33KB
- ocgn-20240102_pre.xml (EX-101.PRE) — 22KB
- tm242262d1_8k_htm.xml (XML) — 3KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 2, 2024, the Compensation Committee (the " Committee ") of the Board of Directors of Ocugen, Inc. (the " Company ") granted certain Performance Restricted Stock Units (the " PSUs ") to certain officers of the Company as part of the Company's annual long term incentive equity grants, including Dr. Shankar Musunuri, the Company's Chief Executive Officer. The PSUs will vest at the end of a three year performance period (ending on December 31, 2026) based upon the total shareholder return (" TSR ") of the Company's common stock, par value $0.01 per share (" Common Stock ") relative to the TSR of the other companies in the Nasdaq Biotechnology Index at the beginning of the three year performance period. The maximum achievement under the PSUs is 200%, and, if actual TSR during the performance period is negative, then the maximum payout for the relative TSR performance will not exceed 100%, regardless of relative TSR performance during the performance period. Dr. Musunuri was awarded 409,836 PSUs. The foregoing description of the PSUs does not purport to be complete and is subject to, and qualified in its entirety by, the form of Performance Restricted Stock Unit Award Agreement, which is filed and attached hereto as Exhibit 10.1, and is incorporated herein by reference.
01 Financial
Item 9.01 Financial The following exhibits are being filed herewith: (d) Exhibits Exhibit No. Document 10.1 Form of Performance Restricted Stock Unit Award Agreement 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 8, 2024 OCUGEN, INC. By: /s/ Shankar Musunuri Name: Shankar Musunuri Title: Chairman, Chief Executive Officer, & Co-Founder